Blastic plasmacytoid dendritic cell neoplasia (BPDCN) is an aggressive hematologic malignancy originating from immature plasmacytoid dendritic cell (PDC) precursors. The initial manifestation of BPDCN often consists of cutaneous lesions. In this educational article, the clinical, histologic and therapeutic aspects of BPDCN are discussed from a dermatologic perspective.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Chronic Urticaria: Treatment for Patients Unresponsive to Antihistamines
In addition to anti-IgE antibodies, the guideline recommends anti-IL-4α antibodies and BTK inhibition
- Type 1 Diabetes in Childhood
Early Impairment of Glucagon Counterregulation
- Psychosis in Parkinson's Disease
Be Careful When Choosing Medications
- Esophageal Cancer
A Comparison of Endoscopic and Surgical Innovations
- PMR and LVV: Current EULAR Recommendations
Polymyalgia rheumatica, giant cell arteritis, and Takayasu arteritis
- Cellular and Systemic Iron Homeostasis
“Steady State” – a delicately balanced equilibrium
- Psychedelic-assisted therapy
Current status of PAT
- First-line treatment for T2D